Bio-Rad's Q4 Earnings Miss Estimates, Revenues Surpass, Stock Down

Key Takeaways BIO posted Q4 adjusted EPS of $2.51, missing estimates as shares sank 12.3%. BIO revenues rose 3.8% to $693.2M, led by Clinical Diagnostics growth of 8.4%. BIO guided 2026 currency-neutral revenue growth of 0.5-1.5% with 12-12.5% margin outlook.Bio-Rad Laboratories, Inc. (BIO) posted fourth-quarter 2025 adjusted earnings per share (EPS) of $2.51, which missed the Zacks Consensus Estimate by 2.3%. The bottom line decreased 13.4% from the prior-year quarter’s level.The quarter’s adjustments prim ...